This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound according to the general Formula (I)



(I)

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof or prodrugs thereof, wherein :

n	is an integer, equal to1;
m	is an integer, equal to 1;
p	is an integer equal to 1;
q	is an integer equal to 0;
Q	is O;
X	is a covalent bond;
~~each~~ R^1	is ~~independently~~ Ar^1 or Ar^1-alkyl;
R^2	is Ar^2 optionally substituted with one or more polyhaloalkyl radicals;
Y	is a covalent bond or a bivalent radical of formula -C(=O)- or -SO_2-;
each Alk	is independently from each other, a covalent bond ; a bivalent straight, saturated hydrocarbon radical having from 1 to 6 carbon atoms; or a cyclic saturated or unsaturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more phenyl radicals;
L	is hydrogen, alkyl, mono- or di(alkyloxycarbonyl)amino, Ar^3, or Het^2;
Ar^1	is phenyl;
Ar^2	is phenyl, optionally substituted with 1, 2 or 3 alkyl substituents ;
Ar^3	is phenyl, optionally substituted with 1 or 2 substituents, each independently halo or cyano;
Het^2	is a monocyclic heterocyclic radical that is pyrrolidinyl, tetrahydrofuranyl, pyrazolyl, furanyl, thienyl, thiadiazolyl, pyridinyl or pyrimidinyl, each radical

optionally substituted with one or more alkyl or alkyloxycarbonyl radicals; and

alkyl is a straight saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon.

2. (Canceled)

3. (Previously Presented) A compound according to claim 1 wherein R^1 is Ar^1methyl and attached to the 2-position or R^1 is Ar^1 and attached to the 3-position.

4. (Previously Presented) A compound according to claim 1 wherein the R^2-X-C(=Q)- moiety is 3,5-di-(trifluoromethyl) phenylcarbonyl.

5. (Canceled)

6. (Previously Presented) A compound according to claim 1 wherein Y is -C(=O)-.

7. (Previously Presented) A compound according to claim 1 wherein Alk is a covalent bond.

8. (Previously Presented) A compound according to claim 1 wherein L is Het^2.

9. (Previously Presented) A compound that is

(2R-trans) [4-(4-azetidin-3-yl-piperazin-1-yl)-2-benzyl-piperidin-1-yl]-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans){4-[4-(1-benzoyl-azetidin-3-yl)-piperazin-1-yl]-2-benzyl-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans)3-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidine-1-carbonyl)-benzonitrile;

(2R-trans) (2-benzyl-4-{4-[1-(3,4-difluoro-benzoyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(pyridine-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(2,5-dimethyl-*2H*-pyrazole-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(thiophene-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(furan-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) {2-benzyl-4-[4-(1-cyclopropanecarbonyl-azetidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-((*3R*) tetrahydro-furan-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-((*3S*) tetrahydro-furan-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) [2-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-carbamic acid *tert*-butyl ester;

(2R-trans) 1-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidin-1-yl)-2-phenyl-propan-1-one;

(2R-trans) (2-benzyl-4-{4-[1-(thiophene-2-sulfonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans)1-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidin-1-yl)-2,2-dimethyl-propan-1-one;

(2R-trans) (2-benzyl-4-{4-[1-(2-chloro-benzoyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) {2-benzyl-4-[4-(1-pyrazin-2-yl-azetidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(pyrazine-2-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) 2-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidine-1-carbonyl)- (*2R*) pyrrolidine-1-carboxylic acid *tert*-butyl ester; or

(2R-trans) 2-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidine-1-carbonyl)- (*2S*) pyrrolidine-1-carboxylic acid *tert*-butyl ester.

10. (Canceled)

11. (Canceled)

12. (Currently Amended) A method for treating a patient suffering from schizophrenia, emesis, anxiety, depression, irritable bowel syndrome ~~(IBS)~~, circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorders or nociception, comprising administering to the patient a therapeutically effective amount of a compound according to claim 1.

13. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

14. (Previously Presented) A process for preparing a pharmaceutical composition comprising mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound of claim 1.

15. (Currently Amended) A process for the preparation of a compound of Formula (I") in which an intermediate compound of Formula (II) is reacted with an intermediate compound of Formula (III)



(II) (III) (I")

wherein

X is a covalent bond;

~~each~~ R^1 is ~~independently~~ Ar^1 or Ar^1-alkyl, wherein Ar^1 is phenyl;

R^2 is Ar^2 wherein Ar^2 is phenyl, optionally substituted with 1, 2 or 3 alkyl substituents or optionally substituted with one or more polyhaloalkyl radicals;

n is an integer, equal to 1;

m is an integer, equal to 1;

p is an integer equal to 1;

q is an integer equal to 0; and

Q is O.

16. (Currently Amended) A process for the preparation of a compound of Formula (I') in which a final compound of Formula (I") is reductively hydrogenated



(I") (I')

wherein

X is a covalent bond;

~~each~~ R^1 is ~~independently~~ Ar^1 or Ar^1-alkyl, wherein Ar^1 is phenyl;

R^2 is Ar^2 wherein Ar^2 is phenyl, optionally substituted with 1, 2 or 3 alkyl substituents or optionally substituted with one or more polyhaloalkyl radicals;

n is an integer, equal to 1;

m is an integer, equal to 1;

p is an integer equal to 1;

q is an integer equal to 0; and

Q is O.

17. (Currently Amended) A process for the preparation of a compound according to Formula (I') comprising

preparing a compound of Formula (I") in which an intermediate compound of Formula (II) is reacted with an intermediate compound of Formula (III)



(II) (III) (I")

wherein

X is a covalent bond;

R^1 is Ar^1 or Ar^1-alkyl, wherein Ar^1 is phenyl;

R^2 is Ar^2, wherein Ar^2 is phenyl, optionally substituted with 1, 2 or 3 alkyl substituents or optionally substituted with one or more polyhaloalkyl radicals;

n is an integer, equal to 1;

m is an integer, equal to 1;

p is an integer equal to 1;

q is an integer equal to 0; and

Q is O; and

preparing a compound of Formula (I') in which a final compound of Formula (I") is reductively hydrogenated



(I") (I')

wherein

X is a covalent bond;

R^1 is Ar^1 or Ar^1-alkyl, wherein Ar^1 is phenyl;

R^2 is Ar^2, wherein Ar^2 is phenyl, optionally substituted with 1, 2 or 3 alkyl substituents or optionally substituted with one or more polyhaloalkyl radicals;

n is an integer, equal to 1;

m is an integer, equal to 1;

p is an integer equal to 1;

q is an integer equal to 0; and

Q is O.

~~the consecutive steps of~~

~~1) obtaining a compound of Formula (I") according to claim 15 ;~~

~~2) obtaining a compound of Formula (I') according to claim 16~~